TNFRSF9 and atherosclerosis: The CD137:CD137L immune checkpoint promotes vascular inflammation as CD137−/−ApoE−/− and CD137−/−LDLR−/− mice had reduced atherosclerotic lesions and inflammation [75] and anti-CD137 antibody decreased atherosclerosis lesion in ApoE−/− mice [76].